Management of comorbidities in ankylosing spondylitis

American Journal of the Medical Sciences

Volumn 343, Issue 5, 2012, Pages 364-366

  Rosenbaum, James ^a   Chandran, Vinod ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Ankylosing spondylitis; Atherosclerosis; Inflammatory bowel disease; Osteoporosis; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; SCOPOLAMINE;

ANKYLOSING SPONDYLITIS; COLONOSCOPY; COMORBIDITY; CONFERENCE PAPER; CORTICOSTEROID THERAPY; ENTERITIS; HEART DISEASE; HEART INFARCTION; HUMAN; NONHUMAN; OSTEOPOROSIS; PRACTICE GUIDELINE; PSORIASIS; STROKE; UVEITIS; VERTEBRA FRACTURE;

EID: 84860802729     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182514059     Document Type: Conference Paper

References (19)

1. Bremander A, Petersson IF, Bergman S, et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011;63:550-6.
2. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51. (Pubitemid 41117431)
3. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006;20:451-71. (Pubitemid 43843072)
4. Evans JM, McMahon AD, Murray FE, et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997;40:619-22. (Pubitemid 27278329)
5. Talley NJ, Abreu MT, Achkar JP, et al; American College of Gas-troenterology IBD Task Force. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroen-terol 2011;106(suppl 1):S2-25; quiz S26.
6. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset inflammatory bowel disease in patients with anky-losing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47. (Pubitemid 46764055)
7. Mathieu S, Gossec L, Dougados M, et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:557-63.
8. Peters MJ, Visman I, Nielen MM, et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010;69:579-81.
9. Vosse D, Landewé R, van der Heijde D, et al. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009;68:1839-42.
10. Maksymowych WP, Gladman D, Rahman P, et al; Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada. The Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. J Rheumatol 2007;34:2273-84. (Pubitemid 350076891)
11. Rosenzweig HL, Planck SR, Rosenbaum JT. NLRs in immune privileged sites. Curr Opin Pharmacol 2011;11:423-8.
12. Willingham SB, Allen IC, Bergstralh DT, et al. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and-independent pathways. J Immunol 2009;183:2008-15.
13. Keystone EC, Schorlemmer HU, Pope C, et al. Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway complement. Arthritis Rheum 1977;20:1396-401.
14. Martin TM, Zhang G, Luo J, et al. A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease. Arthritis Rheum 2005;52:269-74. (Pubitemid 40129257)
15. Buzás EI, Brennan FR, Mikecz K, et al. A proteoglycan (aggrecan)-specific T cell hybridoma induces arthritis in BALB/c mice. J Immunol 1995;155:2679-87.
16. van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31. (Pubitemid 351705922)
17. Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-23. (Pubitemid 44838928)
18. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59: 996-1001. (Pubitemid 351990997)
19. Kezic JM, Davey MP, Glant TT, et al. IFNg regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondyloarthritis. Arthritis Rehum 2012;64:767-771.